At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Bortezomibdrug
Likely dose
Bortezomib 1.3 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Subcutaneous Bortezomib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
In Brief
A Phase 2 clinical trial evaluating Bortezomib for Leukemia. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if bortezomib can help to control MDS. The safety of this drug will also be studied. Bortezomib is designed to block a protein that causes cells to grow. This may cause cancer cells to die.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartAug 2013
Primary CompletionJan 2017
TodayJul 2026
First PostedJul 3, 2013
Enrollment StartAug 7, 2013
Primary CompletionJan 18, 2017
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 13.0 years ago
Interventions
Bortezomibdrug
1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.